PARAMUS, N.J., Jan. 10, 2013 /PRNewswire/ -- Proteonomix, Inc.
(the "Company") (OTC Pink: PROT), a biotechnology company (the
"Company") focused on developing therapeutics based upon the use of
human cells and their derivatives, announced today that upon its
name change to StromaCel, Inc., presently scheduled for
January 18, 2013, all shareholders
will be required to submit their stock certificates to our transfer
agent, VStock Transfer, in order to obtain their new share
certificates in the Company.
About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing
therapeutics based upon the use of human cells and their
derivatives. StromaCel, our subsidiary, develops therapeutic
modalities for the treatment of cardiovascular disease and for
treatment of patients who have suffered post-myocardial infarction.
Proteonomix Regenerative Translational Medicine Institute, Inc.
(PRTMI) intends to focus on the translation of promising research
in stem cell biology and cellular therapy to clinical applications
of regenerative medicine. National Stem Cell, Inc. is prosecuting
patent applications licensed to it.
Forward-looking statements:
Certain statements contained herein are "forward-looking
statements" (as defined in the Private Securities Litigation Reform
Act of 1995). Proteonomix, Inc. cautions that statements made in
this press release constitute forward-looking statements and makes
no guarantee of future performance. Actual results or developments
may differ materially from projections. Forward-looking statements
are based on estimates and opinions of management at the time
statements are made.
SOURCE Law Offices of Roger L.
Fidler